アルツハイマー型認知症（AD）治療薬の世界市場：画期的医薬品の市場機会及び商用化...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Large and Innovative Pipeline 4
2.2 Therapies Promoting Neuronal Survival and Plasticity Show Promise in Early-Stage Development 4
2.3 Extensive Investment in Amyloid-Beta-Targeting Programs despite Historically High Attrition Rates in Clinical Evaluation 4
2.4 Active Deals Landscape with Numerous Investment Opportunities 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9
3.5 Sustained Innovation 9
3.6 GBI Research Report Guidance 10
4 Clinical and Commercial Landscape 11
4.1 Disease Overview 11
4.2 Disease Symptoms 11
4.3 Disease Etiology 11
4.3.1 Genetics 11
4.3.2 Predisposing Medical Conditions and Risk Factors 12
4.4 Pathophysiology 13
4.4.1 Amyloidosis 13
4.4.2 Tau Hyperphosphorylation 14
4.4.3 Receptor for Advanced Glycation Endproducts Signaling 14
4.4.4 Oxidative Stress 14
4.4.5 Neuroinflammation 14
4.5 Comorbidities/Complications 15
4.6 Diagnosis 15
4.6.1 Tools for Screening Cognitive Function 15
4.6.2 Imaging Tests 16
4.6.3 Cerebral Spinal Fluid Testing 17
4.6.4 Blood Tests 17
4.7 Prognosis 18
4.8 Treatment Options 18
4.8.1 Treatment Algorithm 18
4.8.2 Non-Pharmacological Treatments 19
4.9 Current Unmet Needs 19
5 Assessment of Product Pipeline Innovation 21
5.1 Alzheimer’s Disease Pipeline by Molecule Type, Phase and Therapeutic Target 21
5.2 Mechanisms of Action within the Alzheimer’s Disease Pipeline 23
5.3 Comparative Distribution of Programs with First-in-Class and Established Molecular Targets 24
5.4 Pipeline Programs Targeting Established Molecular Targets 26
5.5 First-in-Class Pipeline Programs with Novel Molecular Targets 31
6 Signaling Network, Genetics and Innovation Alignment 35
6.1 The Complexity of Genetic Risk Factors in AD 35
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 36
6.3 First-in-Class Target Matrix Assessment 38
7 First-in-Class Target Evaluation 39
7.1 Pipeline Programs Targeting Calpain 39
7.2 Pipeline Programs Targeting γ -Secretase 41
7.3 Pipeline Programs Targeting Brain-Derived Neurotrophic Factor 44
7.4 Pipeline Programs Targeting Apolipoprotein E 46
7.5 Pipeline Programs Targeting β-Site Amyloid Precursor Protein Cleaving Enzyme 1 48
7.6 Pipeline Programs Targeting Amyloid Precursor Protein and Amyloid-Beta 50
7.7 Pipeline Programs Targeting Casein Kinase 56
7.8 Pipeline Programs Targeting Nerve Growth Factor 57
7.9 Pipeline Programs Targeting Kynurenine 3-Monooxygenase 59
7.10 Pipeline Programs Targeting Leucine -Rich Repeat Kinase -2 60
7.11 Pipeline Programs Targeting Insulin- Regulated Aminopeptidase 61
7.12 Pipeline Programs Targeting Tau 61
7.13 Pipeline Programs Targeting Cathepsin B 65
7.14 Pipeline Programs Targeting Receptor for Advanced Glycation End-products 67
7.15 Pipeline Programs Targeting Protein Phosphatase 2a 69
7.16 Pipeline Programs Targeting Caspase 69
7.17 Pipeline Programs Targeting Cyclin Dependent Kinase 5 71
7.18 Conclusion 73
8 Deals and Strategic Consolidations 75
8.1 Trends in Licensing Deals Across the Entire Pharmaceutical Industry 75
8.2 Deals and Strategic Consolidations in Alzheimer’s Disease 76
8.2.1 Licensing Deals 76
8.2.2 Molecule type 78
8.2.3 Mechanism of Action 79
8.3 Co-development Deals 82
8.3.1 Molecule Type and Mechanism of Action 83
9 First-In-Class Molecules not Involved in Licensing or Co-development Deals 86
10 Appendix 89
10.1 References 90
10.2 Contact Us 101
10.3 Disclaimer 101